Protocol: PK Bridging ELISA Detecting Total Drug Using Anti-Cetuximab Antibodies
Pharmacokinetic (PK) Bridging ELISA protocol detects total drug (free, partially and fully bound): For use with anti-cetuximab monoclonal antibody products HCA220 and HCA228P
This method provides a procedure for carrying out a PK ELISA with anti-cetuximab antibodies, product codes HCA220 (capture antibody) and HCA228P (detection antibody), and using cetuximab monoclonal antibody for the standard curve.
HCA228P anti-cetuximab antibody does not inhibit the binding of cetuximab to EGFR and can therefore detect total drug – free, partially bound and fully bound. The method should always be used in conjunction with product and batch specific information provided with each vial (see product datasheets). This protocol will need to be adjusted for use with different detection methods and immunoassay technology platforms.
View all of our cetuximab antibodies
MaxiSorp™ and QuantaBlu™ are trademarks of Thermo Fisher Scientific.
Tween® is a registered trademark of ICI Americas Inc.
Payment methods we support: